Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia A Systematic Review

被引:7
|
作者
Heiney, Sue P. [1 ]
Sorrell, McKenzie [4 ,5 ]
Sheng, Jingxi [1 ]
Adams, Swann A. [1 ,2 ]
Nelson, Kathy [1 ]
Nguyen, Lan A. [1 ]
Edwards, Amy [3 ]
Wickersham, Karen E. [1 ]
机构
[1] Arnold Sch Publ Hlth, Coll Nursing, Charleston, SC USA
[2] Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Charleston, SC USA
[3] Univ South Carolina, Thomas Cooper Lib, Charleston, SC USA
[4] USC Sch Med Columbia, Prisma Hlth Midlands, Internal Med Residency Program, Charleston, SC USA
[5] Med Univ South Carolina, Charleston, SC 29425 USA
关键词
chronic myeloid leukemia; systematic review; interventions; adherence; tyrosine kinase inhibitors; patient engagement; MEDICATION ADHERENCE; IMATINIB; THERAPY; DASATINIB; NILOTINIB; PERSISTENCE; IMPACT; COSTS; BENEFICIARIES; GUIDELINES;
D O I
10.1097/COC.0000000000000818
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Lack of adherence to tyrosine kinase inhibitors (TKIs) is a significant problem resulting in incomplete cytogenetic response and increased mortality in patients with chronic myeloid leukemia (CML). Few studies have been conducted on interventions to improve adherence. The authors conducted a systematic review to explore studies that examined the impact of strategies to improve TKI adherence among individuals with CML. Methods: The first 2 authors completed a systematic literature review according to the guidelines in Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA). Studies (n=2633) conducted between 1980 and 2019 were identified through 3 databases and examined for inclusion/exclusion criteria. Results: Fourteen studies were identified which met the eligibility criteria. The studies only examined adherence to imatinib, dasatinib, or nilotinib. Ten of the 14 used large data sets (commercial health insurance plans or Surveillance Epidemiology and End Results [SEER] data) for analysis. The majority of the studies used a cohort design. Adherence was defined and measured in a variety of ways with most studies using 80% or higher as adequate adherence. Strategies not focused on health care costs used a multidisciplinary team approach. Conclusion: Development of evidence to improve treatment adherence to TKIs for CML have relied on large data sets rather than prospective trials. Current studies lack patient focused interventions.
引用
收藏
页码:291 / 298
页数:8
相关论文
共 50 条
  • [1] Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
    Tan, Bee Kim
    Chong, Ping
    Chua, Siew Siang
    Chen, Li-Chia
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2021, 15 : 2563 - 2575
  • [2] A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
    Oezmen, Deniz
    Alpaydin, Duygu Demet
    Saldogan, Muhammed Ali
    Eskazan, Ahmet Emre
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (04) : 411 - 423
  • [3] Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
    Dusetzina, Stacie B.
    Winn, Aaron N.
    Abel, Gregory A.
    Huskamp, Haiden A.
    Keating, Nancy L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) : 306 - 311
  • [4] Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead
    Amitai, Irina
    Leader, Avi
    Raanani, Pia
    [J]. ACTA HAEMATOLOGICA, 2016, 136 (01) : 43 - 44
  • [5] Tyrosine kinase inhibitors in chronic myeloid leukemia
    Sawyers, CL
    Druker, B
    [J]. CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
  • [6] Glycemic Control in Patients Treated with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review
    Spatafora, Laura
    Golemiec, Breanne
    Thabane, Lehana
    Banfield, Laura
    Hillis, Christopher M.
    Samaan, Constantine
    Athale, Uma
    [J]. BLOOD, 2018, 132
  • [7] TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKAEMIA: A SYSTEMATIC REVIEW
    Ferdinand, R.
    Mitchell, S.
    Batson, S.
    Tumur, I.
    [J]. HAEMATOLOGICA, 2012, 97 : 533 - 533
  • [8] Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
    Kekale, Meri
    Talvensaari, Kimmo
    Koskenvesa, Perttu
    Porkka, Kimmo
    Airaksinen, Marja
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 1619 - 1627
  • [9] Arterial Hypertension and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
    Mulas, Olga
    Caocci, Giovanni
    Mola, Brunella
    La Nasa, Giorgio
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [10] Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review
    Katsarou, Dimitra
    Kotanidou, Eleni P.
    Tsinopoulou, Vasiliki Rengina
    Tragiannidis, Athanasios
    Hatzipantelis, Emmanouil
    Galli-Tsinopoulou, Assimina
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2024, 30 (33) : 2631 - 2642